# The Thyroid Test Nobody Reordered

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-thyroid-test-nobody-reordered

> Levothyroxine is dosed by body weight, so losing a lot changes what you need. Across 5,370 matched patients, thyroid testing after starting a GLP-1 was identical to a drug with far smaller weight effects.

## Key points

- ~83% tested within a year, ~130 days to testing, identical in both drug groups.
- Levothyroxine dose tracks body weight, so a big loss can make a correct dose too high.
- The oral GLP-1 adds a separate problem: 33% higher thyroxine exposure taken together.
- The study measured testing, not harm. Under-monitoring is a risk, not an injury.

Levothyroxine dose requirement tracks body weight, so a drug that removes a lot of weight predictably changes the dose someone needs. A 2026 study looked at whether anyone rechecked. Among 5,370 matched patients on stable levothyroxine, thyroid testing after starting a GLP-1 was **indistinguishable** from testing after starting a drug with far smaller weight effects: the same proportion tested, at the same point.[1]

## What was compared

The study emulated a trial using Medicare claims: adults aged 65 and over with type 2 diabetes, on a stable levothyroxine dose, starting either a GLP-1 or an SGLT2 inhibitor, matched one to one on propensity scores. The outcome was simply whether a TSH test was ordered during follow-up.[1]

*Thyroid testing after starting each drug class, across 5,370 matched patients.*

| Measure | GLP-1 receptor agonists | SGLT2 inhibitors |
| --- | --- | --- |
| TSH tested within one year | ~83% | ~83% |
| Mean time to testing | ~130.5 days | ~130.5 days |

The comparator is well chosen. SGLT2 inhibitors also reduce weight, but considerably less than GLP-1 drugs do, so this is not a comparison against no treatment. Two groups whose thyroid-monitoring needs differ were monitored identically.

> Eighty-three percent in both arms. One hundred and thirty days in both arms. Nothing moved.

## Why it should have moved

Levothyroxine is dosed by body weight, and the therapeutic window is narrow enough that people notice when it is wrong: fatigue and [cold intolerance](https://glpwatchdog.org/research/glp1-feeling-cold-and-night-sweats) at one end, palpitations and anxiety at the other. Lose a substantial amount of weight and the dose that was correct becomes too much.

There is a second, separate reason specific to the oral GLP-1: taking it alongside levothyroxine raised total thyroxine exposure by 33% in a dedicated trial, which we covered in [interactions](https://glpwatchdog.org/research/glp1-and-your-other-medications). That is a pharmacokinetic effect on top of the weight effect, and it applies from the first dose rather than after months of loss. Both effects, and how they interact with the morning dosing rules, are covered in [our guide to levothyroxine with a GLP-1](https://glpwatchdog.org/research/levothyroxine-and-a-glp1).

> **The authors’ own conclusion names it a gap and a missed opportunity for timely, weight-responsive thyroid monitoring.** That is unusually direct language for a claims study. It is aimed at prescribers rather than patients, which is why it helps a patient to know about it.

## What the study cannot tell you

- **Whether anyone came to harm.** It measured testing, not outcomes. Under-monitoring is a risk, not an injury.
- **The population is narrow:** Medicare, aged 65 and over, 71.6% women, 87.1% White, with type 2 diabetes.
- **The period was 2011 to 2020**, largely before the modern high-dose weight-loss era. The weight changes involved were smaller than someone on a current dose would experience, which makes the finding conservative rather than weaker.
- **83% is not bad testing in absolute terms.** The finding is not that monitoring was poor; it is that it did not *respond* to a change in need.

## What to do with it

If you take levothyroxine and are starting or already on a GLP-1, this is a reasonable thing to raise: whether your thyroid levels should be rechecked as your weight changes, and when. It is a question rather than a demand, and the answer belongs to whoever manages your thyroid.

It also helps to know what an over-replaced thyroid feels like (palpitations, anxiety, heat intolerance, trouble sleeping), because those symptoms overlap with things people attribute to the GLP-1 itself. Attributing everything to the new drug is the easy mistake when two things changed at once. The GLP-1 itself also raises resting heart rate a little, which [a separate guide](https://glpwatchdog.org/research/glp1-heart-rate-and-palpitations) sets out.

## Frequently asked questions

### Do I need my thyroid rechecked on a GLP-1?

It is worth asking. Levothyroxine dose requirement tracks body weight, so losing a substantial amount can make a previously correct dose too high. The decision belongs with whoever manages your thyroid, but the question is a reasonable one to raise.

### What did the study find?

That testing did not change. Among 5,370 matched patients on stable levothyroxine, about 83% had a TSH test within a year of starting either a GLP-1 or an SGLT2 inhibitor, at a mean of around 130 days. That was identical in both groups, even though, as the authors note, the weight loss seen with GLP-1 therapy makes a dose adjustment more likely.

### Is 83% testing bad?

Not in absolute terms. The finding is not that monitoring was poor but that it did not respond to a change in clinical need. Two situations that differ got the same pattern.

### Does the oral version cause an extra problem?

It has a separate one. Oral semaglutide taken with levothyroxine raised total thyroxine exposure by 33% in a dedicated trial. That is a pharmacokinetic effect that applies from the first dose, on top of any weight-related change.

### What does too much levothyroxine feel like?

Palpitations, anxiety, heat intolerance and difficulty sleeping. Those overlap with effects people attribute to the GLP-1 itself, which is the easy mistake to make when two things changed at once.

## References

1. Chen Y, Du F, Singh Ospina NM, et al. Patterns of TSH test after GLP-1 RAs initiation in patients on levothyroxine: a trial emulation study. The Journal of Clinical Endocrinology and Metabolism. 2026. PMID: 41902399. https://pubmed.ncbi.nlm.nih.gov/41902399/

---

Cite as: GLP Watchdog, Ruth Calder, "The Thyroid Test Nobody Reordered", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/the-thyroid-test-nobody-reordered

Canonical HTML page: https://glpwatchdog.org/research/the-thyroid-test-nobody-reordered

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
